Malaysia IVD Registration: Classification and Dossier Differences Explained

1. Key takeaways

In vitro diagnostic medical devices are regulated within the same Act as other devices in Malaysia but are classified under their own rule set, which sits in Appendix 2 to the First Schedule to the Medical Device Regulations 2012. The two rule sets operate independently. A reagent does not inherit the class of the analyser it runs on, and an instrument does not acquire the class of the assay it performs. Each has to be classified on its own facts, which is why an IVD portfolio cannot be planned by extending the logic applied to the instruments around it.

• IVDs are classified under Appendix 2 to the First Schedule, using rules that are separate from those applied to general medical devices.
• The classification runs on two dimensions at once, the personal risk to the individual and the public health risk, and it produces the same four classes, A, B, C and D.
• Class B, C and D IVDs require an IVD-specific CSDT together with the supporting documents.
• The online application form for an IVD carries modules that general device applications do not, including manufacturer information, grouping, post-market vigilance history, validation information and the registration declaration.
• Class A(S), the sterile sub-class, requires a sterilisation process validation report, and Class A(M), the measuring-function sub-class, requires a measuring function validation report, each submitted together with the DoC.
• An IVD holding a European IVDD or MDR notified body certificate, or a United States 510(k) or PMA, may use the verification pathway under Circular Letter MDA No. 1/2025.

2. Legal basis

Appendix 2 to the First Schedule contains the IVD classification rules. Their distinctive feature is that they assess risk twice: once as the risk that a false result poses to the individual tested, and once as the risk that a false result poses to the population, for example through the transfusion of infected blood or the mismanagement of a transmissible disease. A device that is modest on the first dimension can be elevated by the second. That is why the classes cannot be predicted from the technical complexity of the assay, and why two reagents with similar laboratory behaviour can sit in different classes.

The dossier requirements follow the class. Class B, Class C and Class D IVDs must be filed with an IVD-specific CSDT and its supporting documents. The online form is structured in modules, covering manufacturer information, grouping, post-market vigilance history, validation information and a registration declaration. Within Class A, two sub-classes carry additional evidence obligations: Class A(S) for sterile devices requires a sterilisation process validation report, and Class A(M) for devices with a measuring function requires a measuring function validation report, both filed together with the DoC.

The verification pathway introduced by Circular Letter MDA No. 1/2025, which took effect on 11 March 2025, gives IVDs an alternative route where the product already holds an approval from a recognised jurisdiction, whether a European IVDD or MDR notified body certificate or a United States 510(k) or PMA. For manufacturers whose IVDs already carry CE marking, the certificate frequently serves as the starting point of the evidence rather than as evidence of Malaysian compliance, and the distinction between the two should be preserved throughout the file.

3. Expert insights

The single most consequential difference between an IVD application and a general device application is the vigilance history module. It is a discrete section of the MDA form, not an attachment to a narrative, and it asks about recalls, prohibitions and field safety corrective actions in other jurisdictions. The obligation is to declare these truthfully even where they were resolved, and the consequence of omission is not a correction request but rejection of the entire application. Teams that treat the module as a formality, or that leave it to a colleague who does not have access to the global quality record, create a risk that is entirely avoidable.

A second insight concerns the relationship between the instrument and the assay. It is common for a laboratory platform to hold one class while the reagents run on it hold another, and for the combination to be marketed as a system. The classification analysis must be performed separately for the instrument and for each reagent, and where grouping is intended the grouping rules must be satisfied in their own right. Assuming that the system carries a single class because it is sold as a unit is the IVD version of the misclassification error familiar from general devices.

A third insight is about the value of an existing approval. The verification route is genuinely useful, but it rewards preparation. The evidence that supports a European certificate is organised around European requirements, and a Malaysian file still has to be assembled around the IVD CSDT and the Malaysian modules. Manufacturers that begin by mapping their existing technical documentation onto the CSDT structure, rather than by assuming the certificate will carry the file, convert the route into genuine time saving instead of a false start.

4. Practical recommendations

• Classify every reagent and every instrument separately under Appendix 2, and record the personal risk and public health risk reasoning for each.
• Build the IVD CSDT as the frame of the file from the outset for Class B, C and D products, rather than retrofitting existing documentation to it at submission.
• Complete the vigilance history module from the global quality record, covering recalls, prohibitions and field safety corrective actions in every jurisdiction, and retain the evidence behind each negative answer.
• Identify Class A(S) and Class A(M) products early, since the sterilisation or measuring function validation report and the DoC are filed together and a missing report stops the application.
• Assess eligibility for the verification pathway under Circular Letter MDA No. 1/2025 at the planning stage, and record which certificate is being relied on and for which product.
• Treat an existing CE certificate as the start of the evidence chain, not as a substitute for the Malaysian modules, and keep the two clearly distinguished in the file index.

5. Verification checklist

• □ Appendix 2 to the First Schedule read in full for the IVD classification rules (pending verification).
• □ MDA guidance How to Apply for IVD Medical Device Registration under Act 737 reviewed in its current edition (pending verification).
• □ MDA IVD pages checked for the current lists of IVD CSDT, EPSP and DoC guidance documents (pending verification).
• □ Circular Letter MDA No. 1/2025, effective 11 March 2025, confirmed and read for the verification pathway conditions (pending verification).
• □ Vigilance history for each product reconciled against the global recall, prohibition and field safety corrective action records (pending verification).
• □ Class A(S) and Class A(M) designations checked for every Class A product, with the corresponding validation report present (pending verification).

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Malaysia. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the MDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com